Abstract
Both RAS and transforming growth factor (TGF)-β signaling cascades are central in tumorigenesis and show synergisms depending on tumor stage and tissue context. In this review we focus on the interaction of RAS subeffector proteins with signaling components of the TGF-β family including those of TGF-βs, activins and bone morphogenic proteins. Compelling evidence indicates that RAS signaling is essentially involved in the switch from tumor-suppressive to tumor-promoting functions of the TGF-β family leading to enhanced cancer growth and metastatic dissemination of primary tumors. Thus, the interface of these signaling cascades is considered as a promising target for the development of novel cancer therapeutics. The current pharmacological anti-cancer concepts combating the molecular cooperation between RAS and TGF-β family signaling during carcinoma progression are critically discussed.
Keywords: Activin, BMP, cancer progression, RAS, Smad, targeted therapy, TGF-β.
Current Cancer Drug Targets
Title:The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Volume: 10 Issue: 8
Author(s): M. Grusch, M. Petz, T. Metzner, D. Ozturk, D. Schneller and W. Mikulits
Affiliation:
Keywords: Activin, BMP, cancer progression, RAS, Smad, targeted therapy, TGF-β.
Abstract: Both RAS and transforming growth factor (TGF)-β signaling cascades are central in tumorigenesis and show synergisms depending on tumor stage and tissue context. In this review we focus on the interaction of RAS subeffector proteins with signaling components of the TGF-β family including those of TGF-βs, activins and bone morphogenic proteins. Compelling evidence indicates that RAS signaling is essentially involved in the switch from tumor-suppressive to tumor-promoting functions of the TGF-β family leading to enhanced cancer growth and metastatic dissemination of primary tumors. Thus, the interface of these signaling cascades is considered as a promising target for the development of novel cancer therapeutics. The current pharmacological anti-cancer concepts combating the molecular cooperation between RAS and TGF-β family signaling during carcinoma progression are critically discussed.
Export Options
About this article
Cite this article as:
Grusch M., Petz M., Metzner T., Ozturk D., Schneller D. and Mikulits W., The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy, Current Cancer Drug Targets 2010; 10 (8) . https://dx.doi.org/10.2174/156800910793357943
DOI https://dx.doi.org/10.2174/156800910793357943 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Metals and Metal Derivatives in Medicine
Mini-Reviews in Medicinal Chemistry MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets
Current Medicinal Chemistry Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Molecular Switch of AhR in Repression or Activation of Stem Cell Signaling
Current Signal Transduction Therapy Novel Concepts in the Development of Platinum Antitumor Drugs
Current Medicinal Chemistry - Anti-Cancer Agents The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy
Current Cancer Drug Targets Mechanisms of Anorexia Cancer Cachexia Syndrome and Potential Benefits of Traditional Medicine and Natural Herbs
Current Pharmaceutical Biotechnology ErbB Targeted Drugs and Angiogenesis
Current Vascular Pharmacology Mycotoxins Levels in Human Milk: A Menace to Infants and Children Health
Current Nutrition & Food Science Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Carbonic Anhydrase Based Biomarkers: Potential Application in Human Health and Environmental Sciences
Current Biomarkers (Discontinued) Novel Oral Anticoagulants for Venous Thromboembolism with Special Emphasis on Risk of Hemorrhagic Complications and Reversal Agents
Current Drug Therapy Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms
Current Topics in Medicinal Chemistry Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer
Current Drug Targets MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Current Drug Targets